Spots Global Cancer Trial Database for imatinib mesylate
Every month we try and update this database with for imatinib mesylate cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Imatinib Mesylate in Treating Patients With Gastrointestinal Stromal Tumor That Has Been Completely Removed During Surgery | NCT00025246 | Gastrointestina... | imatinib mesyla... laboratory biom... | 16 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy and Imatinib Mesylate in Treating Children With Relapsed Acute Lymphoblastic Leukemia | NCT00049569 | L1 Childhood Ac... L2 Childhood Ac... Non-T, Non-B Ch... Recurrent Child... T-cell Childhoo... | cytarabine methotrexate vincristine sul... prednisone pegaspargase doxorubicin hyd... imatinib mesyla... cyclophosphamid... etoposide filgrastim leucovorin calc... asparaginase therapeutic hyd... | 1 Year - 21 Years | National Cancer Institute (NCI) | |
| Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM) | NCT00290771 | Recurrent Gliob... | Imatinib tablet... Hydroxyurea cap... | 18 Years - | Novartis | |
| Study of Imatinib in Children With Neurofibromatosis and Airway Tumors | NCT03688568 | Neurofibroma, P... | Imatinib Mesyla... | 6 Months - 12 Years | Indiana University | |
| Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors | NCT00427583 | Malignant Perip... | imatinib mesyla... | 18 Years - | Novartis | |
| STI571 in Treating Patients With Recurrent Leukemia | NCT00004932 | Leukemia | imatinib mesyla... | - 21 Years | Children's Oncology Group | |
| Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors | NCT00372567 | Gastrointestina... | sunitinib malat... imatinib mesyla... | 18 Years - | Pfizer | |
| Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia | NCT02709083 | Chronic Myeloge... Chronic Myeloid... Leukemia | Dasatinib Imatinib Mesyla... Nilotinib | 17 Years - | Emory University | |
| Everolimus in Combination With Imatinib Mesylate in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Soft Tissue Sarcoma | NCT01281865 | Adult Synovial ... Recurrent Adult... Stage III Adult... Stage IV Adult ... | diagnostic labo... everolimus imatinib mesyla... | 18 Years - | National Cancer Institute (NCI) | |
| Gleevec Administered Preoperatively to Reduce Gastrointestinal Stromal Tumor (GIST) | NCT00290485 | Gastrointestina... | Imatinib mesyla... | 18 Years - | Maisonneuve-Rosemont Hospital | |
| Combined Antiinflammatory and Angiostatic Therapy in Patients With Hormone-refractory Prostate Cancer | NCT00427999 | Prostate Cancer | imatinib mesyla... Treosulfane etoricoxib pioglitazone dexamethasone | 18 Years - | Novartis | |
| Imatinib Mesylate and Bevacizumab After First-Line Chemotherapy and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | NCT00425646 | Lung Cancer | bevacizumab imatinib mesyla... | 18 Years - | University of Washington | |
| Study of Imatinib Mesylate in Neurofibromatosis Type I Patients Aged 2 to 21 With Plexiform Neurofibromas | NCT02177825 | Plexiform Neuro... | Imatinib Mesyla... | 2 Years - 21 Years | St. Justine's Hospital | |
| Preoperative and Postoperative Imatinib Mesylate Study in Patients With c-Kit Positive GIST | NCT00500188 | Gastrointestina... | Imatinib Mesyla... | - | M.D. Anderson Cancer Center | |
| Use and Tolerability of Imatinib Mesylate (Gleevec) in Leukemia Patients | NCT00386373 | Leukemia | Imatinib Mesyla... | 16 Years - | M.D. Anderson Cancer Center | |
| Imatinib Mesylate in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer | NCT00041041 | Primary Periton... Recurrent Ovari... | imatinib mesyla... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Therapy of Early Chronic Phase CML With Gleevec | NCT00048672 | Leukemia, Myelo... | Gleevec | 15 Years - | M.D. Anderson Cancer Center | |
| A Dose-finding Study of a Combination of Imatinib and BYL719 in the Treatment of 3rd Line GIST Patients | NCT01735968 | 3rd Line GIST | ST571 + BYL719 | 18 Years - | Novartis | |
| Chemotherapy, Imatinib Mesylate, and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | NCT00039377 | Adult Acute Lym... | imatinib mesyla... methotrexate vincristine sul... leucovorin calc... peripheral bloo... autologous hema... allogeneic hema... total-body irra... tacrolimus filgrastim etoposide cyclophosphamid... cytarabine laboratory biom... | 15 Years - 59 Years | National Cancer Institute (NCI) | |
| Imatinib Mesylate After a Donor Stem Cell Transplant in Treating Patients With Philadelphia Chromosome-Positive Leukemia | NCT00244829 | Leukemia | imatinib mesyla... adjuvant therap... | - | Fred Hutchinson Cancer Center | |
| Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors | NCT01751425 | Chronic Myeloge... Chronic Myeloge... Minimal Residua... Philadelphia Ch... | Dasatinib Imatinib Mesyla... Nilotinib Ruxolitinib | 18 Years - | M.D. Anderson Cancer Center | |
| Everolimus in Combination With Imatinib Mesylate in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Soft Tissue Sarcoma | NCT01281865 | Adult Synovial ... Recurrent Adult... Stage III Adult... Stage IV Adult ... | diagnostic labo... everolimus imatinib mesyla... | 18 Years - | National Cancer Institute (NCI) | |
| Oblimersen and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia | NCT00049192 | Chronic Myeloge... Chronic Phase C... Relapsing Chron... | oblimersen sodi... imatinib mesyla... laboratory biom... | 15 Years - | National Cancer Institute (NCI) | |
| Imatinib Mesylate (Gleevec) and Docetaxel in Patients With Head and Neck Squamous Cell Cancer | NCT00485485 | Head and Neck C... Squamous Cell C... | Imatinib Mesyla... Docetaxel | 18 Years - | M.D. Anderson Cancer Center | |
| STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma | NCT00006357 | Endometrial Can... Gastrointestina... Ovarian Cancer Sarcoma Small Intestine... | imatinib mesyla... | 15 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Tumor Tissue Analysis in Patients Receiving Imatinib Mesylate for Malignant Glioma | NCT00401024 | Brain and Centr... | imatinib mesyla... pharmacological... conventional su... | 18 Years - 120 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Phase II Clinical Study of Imatinib Mesylate in Patients With Malignant Gastrointestinal Stromal Tumors (Extension Study) | NCT00237172 | Gastrointestina... | Imatinib Mesyla... | 20 Years - 74 Years | Novartis | |
| Docetaxel (Taxotere) and Imatinib Mesylate (Gleevec) in Hormone Refractory Prostate Cancer | NCT00861471 | Prostate Cancer Prostatic Neopl... | Docetaxel Imatinib Mesyla... | 18 Years - | NYU Langone Health | |
| Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML Patients | NCT00499889 | Leukemia | Imatinib Mesyla... Fludarabine (Fl... Busulfan Antithymocyte G... Tacrolimus Methotrexate Donor lymphocyt... Stem Cell Trans... | - 70 Years | M.D. Anderson Cancer Center | |
| An Extension Study to Determine the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Participants With Ph+ Leukemia | NCT00171249 | Philadelphia Po... Acute Lymphobla... Acute Myeloid L... | STI571 400 mg STI571 600 mg | 18 Years - | Novartis | |
| STI571 Compared With Interferon Alfa Plus Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia | NCT00006343 | Leukemia | recombinant int... cytarabine imatinib mesyla... | 18 Years - 70 Years | Novartis | |
| A Study of the Efficacy and Safety of Imatinib Mesylate in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing C-kit Gene | NCT00237185 | Unresectable or... | Imatinib mesyla... | 18 Years - | Novartis | |
| Efficacy Study of Imatinib Mesylate to Treat Philadelphia-Positive Acute Lymphocytic Leukemia | NCT00154349 | Philadelphia Ch... | Imatinib Mesyla... | 15 Years - | Novartis | |
| Study of Imatinib in Children With Neurofibromatosis and Airway Tumors | NCT03688568 | Neurofibroma, P... | Imatinib Mesyla... | 6 Months - 12 Years | Indiana University | |
| New Individualized Therapy Trial for Metastatic Colorectal Cancer | NCT00867334 | Colorectal Neop... Colorectal Canc... | Imatinib mesyla... Standard-of-car... | 18 Years - | Inova Health Care Services | |
| Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors | NCT00427583 | Malignant Perip... | imatinib mesyla... | 18 Years - | Novartis | |
| Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma | NCT00010049 | Brain and Centr... | imatinib mesyla... | 18 Years - 120 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate | NCT00038675 | Chronic Myelomo... Chronic Myeloid... Polycythemia Ve... Hypereosinophil... Mastocytosis | Imatinib Mesyla... | - | M.D. Anderson Cancer Center | |
| Imatinib Mesylate With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed or Recurrent Glioma | NCT00021229 | Brain and Centr... | imatinib mesyla... local irradiati... | 3 Years - 21 Years | National Cancer Institute (NCI) | |
| Imatinib Mesylate With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed or Recurrent Glioma | NCT00021229 | Brain and Centr... | imatinib mesyla... local irradiati... | 3 Years - 21 Years | National Cancer Institute (NCI) | |
| Imatinib Mesylate in Treating Patients With Salivary Gland Cancer | NCT00045669 | Head and Neck C... | imatinib mesyla... | 18 Years - 120 Years | University Health Network, Toronto | |
| Validation of Digital-PCR Analysis Through Programmed Imatinib Interruption in PCR Negative CML Patients | NCT01578213 | Chronic Myeloid... | Imatinib mesyla... | 18 Years - | University of Milano Bicocca | |
| Imatinib Mesylate in Treating Patients With Metastatic Breast Cancer | NCT00045188 | Male Breast Can... Recurrent Breas... Stage IV Breast... | imatinib mesyla... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+) | NCT01222013 | Acute Lymphobla... | Imatinib Mesyla... | 1 Year - 18 Years | Hospital Santa Marcelina | |
| Imatinib Mesylate, Daunorubicin, and Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia | NCT00268229 | Leukemia | cytarabine daunorubicin hy... imatinib mesyla... | 18 Years - | The Cleveland Clinic | |
| Study Comparing 12 Months Versus 36 Months of Imatinib in the Treatment of Gastrointestinal Stromal Tumor (GIST) | NCT00116935 | Sarcoma | imatinib mesyla... imatinib imatinib | 18 Years - | Scandinavian Sarcoma Group | |
| Imatinib Mesylate in Treating Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumor | NCT00685828 | Gastrointestina... | imatinib mesyla... | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| An Extension Study to Determine the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Participants With Ph+ Leukemia | NCT00171249 | Philadelphia Po... Acute Lymphobla... Acute Myeloid L... | STI571 400 mg STI571 600 mg | 18 Years - | Novartis | |
| Study of Dose Escalation Versus no Dose Escalation of Imatinib in Metastatic Gastrointestinal Stromal Tumors (GIST) Patients | NCT01031628 | Gastrointestina... | Imatinib mesyla... Imatinib mesyla... Imatinib mesyla... | 18 Years - | Sarcoma Alliance for Research through Collaboration | |
| Autologous Transplantation for Chronic Myelogenous Leukemia | NCT01003054 | Chronic Myeloge... | Busulfan Cyclophosphamid... Imatinib Mesyla... Autologous Stem... | - 70 Years | M.D. Anderson Cancer Center | |
| A Phase II Trial of STI571 in the Treatment of Metastatic Gastric Cancer | NCT00068380 | Recurrent Gastr... Stage IV Gastri... | imatinib mesyla... laboratory biom... | 19 Years - | National Cancer Institute (NCI) | |
| Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease | NCT03516279 | Chronic Phase C... Minimal Residua... | Dasatinib Imatinib Mesyla... Laboratory Biom... Nilotinib Pembrolizumab | 18 Years - | Eastern Cooperative Oncology Group | |
| Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation | NCT00990249 | Leukemia Lymphoma Allogeneic Haem... Acute Lymphobla... | Busulfan Clofarabine Thymoglobulin Stem Cell Trans... | - 65 Years | M.D. Anderson Cancer Center | |
| Study of Gleevec and Weekly Paclitaxel in Patients Aged 70 or Older With Advanced Non-small Cell Lung Cancer | NCT01011075 | Non-small Cell ... | Imatinib mesyla... Paclitaxel | 70 Years - | New Mexico Cancer Care Alliance | |
| Imatinib Mesylate and Bevacizumab After First-Line Chemotherapy and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | NCT00425646 | Lung Cancer | bevacizumab imatinib mesyla... | 18 Years - | University of Washington | |
| Imatinib Mesylate in Combination With Docetaxel for Advanced, Platinum-Refractory Ovarian Cancer | NCT00216112 | Ovarian Cancer | Imatinib Mesyla... Docetaxel | 18 Years - | Hoosier Cancer Research Network | |
| Everolimus and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission After Previous Imatinib Mesylate | NCT00093639 | Leukemia | everolimus imatinib mesyla... | 18 Years - | Novartis | |
| Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery | NCT00470470 | Acral Lentigino... Recurrent Melan... Stage IIIA Mela... Stage IIIB Mela... Stage IIIC Mela... Stage IV Melano... | imatinib mesyla... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Efficacy Study of Imatinib Mesylate to Treat Philadelphia-Positive Acute Lymphocytic Leukemia | NCT00154349 | Philadelphia Ch... | Imatinib Mesyla... | 15 Years - | Novartis | |
| High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML) | NCT00050531 | Leukemia, Myelo... | Gleevec Peg-alpha inter... Sargramostim (G... | 18 Years - | M.D. Anderson Cancer Center | |
| Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers | NCT00074308 | Recurrent Melan... Stage III Melan... Stage IV Melano... Unspecified Adu... | imatinib mesyla... bevacizumab pharmacological... laboratory biom... | 21 Years - | National Cancer Institute (NCI) | |
| STI571 in Treating Patients With Accelerated Phase Chronic Myelogenous Leukemia | NCT00006052 | Leukemia | imatinib mesyla... | 18 Years - | Novartis | |
| Comparison of Two Different Doses of STI571 in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor | NCT00009906 | Gastrointestina... | Imatinib Mesyla... | 15 Years - | National Cancer Institute (NCI) | |
| Imatinib Mesylate in Treating Patients With Stage IV Colorectal Cancer | NCT00041340 | Recurrent Colon... Recurrent Recta... Stage IV Colon ... Stage IV Rectal... | imatinib mesyla... laboratory biom... | - | National Cancer Institute (NCI) | |
| Entacapone Combination With Imatinib for Treatment of GIST | NCT04006769 | Gastrointestina... | Entacapone Imatinib Mesyla... | 18 Years - | Xiangya Hospital of Central South University | |
| Gemcitabine and Imatinib Mesylate in Treating Patients With Recurrent or Metastatic Non-Small Cell Lung Cancer | NCT00323362 | Lung Cancer | gemcitabine hyd... imatinib mesyla... | 18 Years - | Rutgers, The State University of New Jersey | |
| A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia | NCT03589326 | Philadelphia Ch... | Ponatinib Imatinib Vincristine Dexamethasone Cytarabine Methotrexate Prednisone | 18 Years - | Takeda | |
| Imatinib Mesylate and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia | NCT00015847 | Leukemia | recombinant int... imatinib mesyla... | 18 Years - | OHSU Knight Cancer Institute | |
| Study of Gleevec and Weekly Paclitaxel in Patients Aged 70 or Older With Advanced Non-small Cell Lung Cancer | NCT01011075 | Non-small Cell ... | Imatinib mesyla... Paclitaxel | 70 Years - | New Mexico Cancer Care Alliance | |
| Imatinib Mesylate With or Without Hydroxychloroquine in Treating Patients With Chronic Myeloid Leukemia | NCT01227135 | Leukemia | hydroxychloroqu... imatinib mesyla... cytogenetic ana... polymerase chai... laboratory biom... pharmacological... | 18 Years - | University of Glasgow | |
| Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Children With Acute Lymphoblastic Leukemia | NCT00022737 | Childhood Acute... Recurrent Child... | filgrastim asparaginase cyclophosphamid... cyclosporine cytarabine daunorubicin hy... dexamethasone etoposide ifosfamide imatinib mesyla... leucovorin calc... mercaptopurine ... methotrexate pegaspargase vincristine sul... allogeneic bone... peripheral bloo... umbilical cord ... radiation thera... | 1 Year - 21 Years | National Cancer Institute (NCI) | |
| Imatinib Mesylate in Treating Patients With Refractory or Relapsed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer, or Ovarian Low Malignant Potential Tumor | NCT00039585 | Fallopian Tube ... Ovarian Cancer Primary Periton... | imatinib mesyla... | - | National Cancer Institute (NCI) | |
| Imatinib Mesylate and Gemcitabine in Treating Patients With Locally Advanced, Metastatic, or Recurrent Pancreatic Cancer | NCT00281996 | Pancreatic Canc... | Gemcitabine Imatinib mesyla... | 18 Years - | Northwestern University | |
| Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/Amplification | NCT02812693 | Stage IIIA Skin... Stage IIIB Skin... Stage IIIC Skin... Stage IV Skin M... | Imatinib Mesyla... Laboratory Biom... Pembrolizumab | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Imatinib Mesylate and Paclitaxel in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | NCT00408460 | Malignant Pleur... Recurrent Non-s... Stage IIIB Non-... Stage IV Non-sm... | imatinib mesyla... paclitaxel | 70 Years - | University of Washington | |
| STI571 in Treating Patients With Chronic Myelogenous Leukemia That Has Not Responded to Interferon Alfa | NCT00006053 | Leukemia | imatinib mesyla... | 18 Years - | Novartis | |
| Flavopiridol and Imatinib Mesylate in Treating Patients With Hematologic Cancer | NCT00064285 | Leukemia | alvocidib imatinib mesyla... | 18 Years - | Virginia Commonwealth University | |
| Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes | NCT00171912 | Hypereosinophil... Systemic Mastoc... Chronic Myelomo... Dermatofibrosar... | imatinib mesyla... | 16 Years - 80 Years | Novartis | |
| Gemcitabine +/- Imatinib Mesylate, Patients w/Previously Treated Metastatic Breast Cancer | NCT00323063 | Breast Cancer | gemcitabine hyd... imatinib mesyla... | 18 Years - 120 Years | Rutgers, The State University of New Jersey | |
| Imatinib Mesylate in Treating Patients With Myelofibrosis | NCT00039416 | Chronic Myelomo... Essential Throm... Polycythemia Ve... Primary Myelofi... | imatinib mesyla... laboratory biom... | 18 Years - | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
